Enter marketing agreement for generic versions of two Upjohn products and are negotiating a second agreement covering additional products, Ciba-Geigy subsidiary Geneva announced March 11. The two products covered by the agreement were not named, but the deal is described as part of Upjohn's strategy to reduce the impact of product patent expirations. Top-selling Upjohn products with patents scheduled to expire in the next few years include: Micronase (glyburide -- April 1992); Ansaid (flurbiprofen -- February 1993); Xanax (alprazolam -- September 1993); and Halcion (triazolam -- September 1993).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth